1-甲基-1H-1,2,3-苯并三唑-5-羰基氯 | 423768-38-1

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并三唑类
• 中文名称: 1-甲基-1H-1,2,3-苯并三唑-5-羰基氯
• 英文名称: 1-methyl-1H-1,2,3-benzotriazole-5-carbonyl chloride
• 英文别名: 1-methylbenzotriazole-5-carbonyl chloride
• CAS: 423768-38-1
• 化学式: C₈H₆ClN₃O
• mdl: MFCD03086164
• 分子量: 195.608
• InChiKey: WNWYKNCOAJIRNK-UHFFFAOYSA-N

物化性质

• 熔点：
  125 °C

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  47.8
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险品标志：
  C
• 安全说明：
  S26,S36/37/39,S45
• 危险类别码：
  R20/21/22,R34
• 海关编码：
  2933990090
• 危险品运输编号：
  UN 3261

SDS

Name:	1-Methyl-1H-1 2 3-benzotriazole-5-carbonyl chloride 97% Material Safety Data Sheet
Synonym:
CAS:	423768-38-1

Section 1 - Chemical Product MSDS Name:1-Methyl-1H-1 2 3-benzotriazole-5-carbonyl chloride 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
423768-38-1	1-Methyl-1H-1,2,3-benzotriazole-5-carb	97	unlisted

Hazard Symbols: C
Risk Phrases: 20/21/22 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed. Causes burns.Moisture sensitive.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Do not induce vomiting. Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area. Store under an inert atmosphere.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 423768-38-1: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: brown
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 123 - 127 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H6ClN3O
Molecular Weight: 195.61

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials, exposure to moist air or water.
Incompatibilities with Other Materials:
Strong oxidizing agents, bases.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 423768-38-1 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1-Methyl-1H-1,2,3-benzotriazole-5-carbonyl chloride - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: CORROSIVE SOLID, TOXIC, N.O.S.*
Hazard Class: 8 (6.1)
UN Number: 2923
Packing Group: III
IMO
Shipping Name: CORROSIVE SOLID, TOXIC, N.O.S.
Hazard Class: 8 (6.1)
UN Number: 2923
Packing Group: III
RID/ADR
Shipping Name: CORROSIVE SOLID, TOXIC, N.O.S.
Hazard Class: 8 (6.1)
UN Number: 2923
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
R 34 Causes burns.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 423768-38-1: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 423768-38-1 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 423768-38-1 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-甲基-1H-1,2,3-苯并三唑-5-羰基氯 、 乙二醇水杨酸酯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 5.0h， 生成 2-(2-hydroxybenzoyloxy)-ethyl-1-methyl-1H-benzo[d][1,2,3]triazole-5-carboxylate
  参考文献：
  名称：

  新型植物活化剂支架的发现：从水杨酸到苯并三唑

  摘要：

  摘要从水杨酸（SA）和相关的商业化植物活化剂开始，基于分子三维形状和药效团相似度比较（SHAFTS），预测了一种新的铅化合物苯并三唑，并设计和合成了一系列苯并三唑衍生物。生物测定表明，苯并三唑在体内对多种疾病（包括真菌和卵菌）具有高活性，但在体外则无活性。并且在1'-位和5'-位引入适当的基团对于该活性是有利的。因此，它们具有被开发为新型植物激活剂的潜力。

  DOI：

  10.1016/j.cclet.2017.02.004
• 作为产物：
  描述：

  4-甲氨基-3-硝基苯甲酸 在 草酰氯 、 硫酸 、 palladium 10% on activated carbon 、 氢气 、 溶剂黄146 、 sodium hydroxide 、 sodium nitrite 作用下， 以 二氯甲烷 、 水 、 溶剂黄146 、 乙酸乙酯 为溶剂， 反应 32.0h， 生成 1-甲基-1H-1,2,3-苯并三唑-5-羰基氯
  参考文献：
  名称：

  新型植物活化剂支架的发现：从水杨酸到苯并三唑

  摘要：

  摘要从水杨酸（SA）和相关的商业化植物活化剂开始，基于分子三维形状和药效团相似度比较（SHAFTS），预测了一种新的铅化合物苯并三唑，并设计和合成了一系列苯并三唑衍生物。生物测定表明，苯并三唑在体内对多种疾病（包括真菌和卵菌）具有高活性，但在体外则无活性。并且在1'-位和5'-位引入适当的基团对于该活性是有利的。因此，它们具有被开发为新型植物激活剂的潜力。

  DOI：

  10.1016/j.cclet.2017.02.004

文献信息

• 2-Pyrimidinyl Pyrazolopyridine Erbb Kinase Inhibitors
  申请人：Uehling Edward David

  公开号：US20080051395A1

  公开（公告）日：2008-02-28

  The present invention provides 2-pyrimidinyl pyrazolopyridine compounds, compositions containing the same, as well as processes for the preparation and their use as pharmaceutical agents.

  本发明提供了2-嘧啶基吡唑吡啶化合物，含有这些化合物的组合物，以及其制备过程和作为药物剂的用途。
• Organic Compounds
  申请人：Fairhurst Robin Alec

  公开号：US20100286126A1

  公开（公告）日：2010-11-11

  A compound of formula (I) or stereoisomers or pharmaceutically acceptable salts thereof, and their preparation and use as pharmaceuticals wherein R 1 , R 2 and R 3 are as defined herein.

  化合物的公式（I）或其立体异构体或药用可接受的盐，以及它们的制备和用途作为药物，其中R1、R2和R3如本文所定义。
• [EN] PIPERIDINE-BENZENESULFONAMIDE DERIVATIVES<br/>[FR] DERIVES DE PIPERIDINE-BENZENESULFONAMIDE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2004072034A1

  公开（公告）日：2004-08-26

  The present invention relates to compounds of the general formula (I) wherein R1 is lower alkyl, -(CH2)n-aryl, unsubstituted or substituted by one or two substituents, selected from the group consisting of lower alkyl, lower alkoxy, -OCF3, halogen, -NR’R” or trifluoromethyl, or heteroaryl; R2 is lower alkyl, -(CH2)n-aryl, unsubstituted or substituted by one or two substituents, selected from the group consisting of lower alkyl, lower alkoxy, halogen, trifluoromethyl, nitro, cyano, -NR’R”, hydroxy, or by a heteroaryl group, or is heteroaryl, unsubstituted or substituted by one or two substituents, selected from the group consisting of lower alkyl or halogen; R3 is heteroaryl or is aryl, unsubstituted or substituted by halogen or lower alkyl; R4 is hydrogen or hydroxy; A is -S(O)2-or-C(O)-; X,Y are independently from each other -CH2- or -O-, with the proviso that X and Y are not simultaneously -O; R’R” are independently from each other hydrogen, lower alkyl or -C(O)-lower alkyl; n is 0, 1 or 2; and to pharmaceutically acceptable acid addition salts thereof. The compounds may be used for the treatment of psychoses, pain, disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer’s disease.

  本发明涉及一般式（I）的化合物，其中R1为较低的烷基，-(CH2)n-芳基，未取代或被选自较低烷基、较低烷氧基、-OCF3、卤素、-NR’R”或三氟甲基的一种或两种取代基所取代，或杂芳基；R2为较低的烷基，-(CH2)n-芳基，未取代或被选自较低烷基、较低烷氧基、卤素、三氟甲基、硝基、氰基、-NR’R”、羟基，或由杂芳基所取代的一种或两种取代基，或为杂芳基，未取代或被选自较低烷基或卤素的一种或两种取代基；R3为杂芳基或为芳基，未取代或被卤素或较低烷基所取代；R4为氢或羟基；A为-S(O)2-或-C(O)-；X，Y分别为-CH2-或-O-，但X和Y不能同时为-O；R’R”分别为氢、较低烷基或-C(O)-较低烷基；n为0、1或2；以及其药学上可接受的酸盐。这些化合物可用于治疗精神病、疼痛、记忆和学习功能障碍、精神分裂症、痴呆症和其他认知过程受损的疾病，如注意力缺陷障碍或阿尔茨海默病。
• [EN] PHENYL-PIPERIDIN-4-YLIDENE-METHYL-BENZAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN OR GASTROINTESTINAL DISORDERS<br/>[FR] DERIVES DE PHENYL-PIPERIDIN-4-YLIDENE-METHYL-BENZAMIDE POUR LE TRAITEMENT DE LA DOULEUR ET DE TROUBLES GASTRO-INTESTINAUX
  申请人：ASTRAZENECA AB

  公开号：WO2004041784A1

  公开（公告）日：2004-05-21

  Compounds of general formula: wherein R1, R2 and R3 are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

  通式化合物：其中R1、R2和R3如规范中定义，以及它们的盐、对映体和包括这些化合物的药物组合物已准备好。它们在治疗中很有用，特别是在疼痛管理中。
• Substituted heteroaryl pyridopyrimidone derivatives
  申请人：Sanofi-Aventis

  公开号：EP1939187A1

  公开（公告）日：2008-07-02

  A pyrimidone derivative represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof : wherein: Y represents two hydrogen atoms, a sulfur atom, an oxygen atom or a C1-2 alkyl group and a hydrogen atom; Z represents a bond, an oxygen atom, a nitrogen atom, a sulphur atom, a methylene group optionally substituted by one or two groups chosen from a C1-6 alkyl group, a hydroxyl group, a C1-6 alkoxy group, a C1-2 perhalogenated alkyl group or an amino group; R1 represents a 2, 3 or 4-pyridine ring or a 2, 4 or 5-pyrimidine ring; R2 represents a 4-15 membered heterocyclic group , R3 represents a hydrogen atom, a C1-6 alkyl group or a halogen atom; R4 and R5 represent, each independently, a hydrogen atom, a C1-6 alkyl group, optionally substituted by 1 to 4 substituents selected from a halogen atom, a phenyl group, a hydroxyl group or a C1-6 alkoxy group; R6 represents a hydrogen atom, a C1-6 alkyl group ; a cycloalkyl group, or a halogen atom; R7 represents a hydrogen atom or a C1-6 alkyl group; n represents 0 to 3; m represents 0 to 1; o represents 0 to 2; in the form of a free base or of an addition salt with an acid. The invention relates also to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β, such as Alzheimer disease.

  公式（I）表示的嘧啶酮衍生物或其盐，溶剂化合物或水合物：其中：Y代表两个氢原子、硫原子、氧原子或C1-2烷基基团和一个氢原子；Z代表键、氧原子、氮原子、硫原子、一个亚甲基基团，可选地由C1-6烷基基团、羟基、C1-6烷氧基、C1-2全卤代烷基或氨基中选择的一种或两种基团取代的亚甲基基团；R1代表2、3或4-吡啶环或2、4或5-嘧啶环；R2代表4-15成员的杂环基团，R3代表氢原子、C1-6烷基基团或卤原子；R4和R5分别代表氢原子、C1-6烷基基团，可选地取代1至4个取代基，所选取代基来自卤原子、苯基、羟基或C1-6烷氧基；R6代表氢原子、C1-6烷基基团；环烷基基团或卤原子；R7代表氢原子或C1-6烷基基团；n表示0到3；m表示0到1；o表示0到2；以自由碱或与酸的加成盐的形式存在。该发明还涉及一种药物，包括所述衍生物或其盐作为活性成分，用于预防和/或治疗由GSK3β异常活性引起的神经退行性疾病，如阿尔茨海默病。